Affordable Access

deepdyve-link
Publisher Website

Caveolin-1 expression predicts favourable outcome and correlates with PDGFRA mutations in gastrointestinal stromal tumours (GISTs).

Authors
  • Bertero, Luca1
  • Gambella, Alessandro1
  • Barreca, Antonella2
  • Osella-Abate, Simona3
  • Chiusa, Luigi2
  • Francia di Celle, Paola3
  • Lista, Patrizia4
  • Papotti, Mauro5
  • Cassoni, Paola6
  • 1 Pathology Unit, Department of Medical Sciences, University of Turin, Turin, Italy. , (Italy)
  • 2 Pathology Unit, "Città della Salute e della Scienza di Torino" University Hospital, Turin, Italy. , (Italy)
  • 3 Molecular Pathology Unit, "Città della Salute e della Scienza di Torino" University Hospital, Turin, Italy. , (Italy)
  • 4 Oncology Unit, "Città della Salute e della Scienza di Torino" University Hospital, Turin, Italy. , (Italy)
  • 5 Pathology Unit, Department of Oncology, University of Turin, Turin, Italy. , (Italy)
  • 6 Pathology Unit, Department of Medical Sciences, University of Turin, Turin, Italy [email protected] , (Italy)
Type
Published Article
Journal
Journal of Clinical Pathology
Publisher
BMJ
Publication Date
Dec 01, 2022
Volume
75
Issue
12
Pages
825–831
Identifiers
DOI: 10.1136/jclinpath-2021-207595
PMID: 34155091
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Novel prognostic markers are warranted for gastrointestinal stromal tumours. Caveolin-1 is a multifunctional protein that proved to be associated with outcome in multiple tumour types. Aim of this study was to investigate Caveolin-1 expression and prognostic efficacy in a series of gastrointestinal stromal tumours. Caveolin-1 expression was assessed by immunohistochemistry in a retrospective series of 66 gastrointestinal stromal tumours representative of the different molecular subtypes. Correlations with clinical, histopathological and molecular features were investigated. Statistical analyses were performed as appropriate. Thirty-five cases out of 66 (53.0%) expressed Caveolin-1. Presence of Caveolin-1 expression correlated with favourable histopathologic and clinical traits, including a lower mitotic count (p=0.003) and lower relapse rate (p=0.005). Caveolin-1 expression also resulted associated with the presence of PDGFRA mutations (p=0.010). Outcome analyses showed a favourable prognostic significance of Caveolin-1 expression in terms of relapse-free survival (HR=0.14; 95% CI=0.03 to 0.63) and overall survival (HR=0.29; 95% CI=0.11 to 0.74), even after adjusting for the mutational subgroup (relapse-free survival: HR=0.14, 95% CI=0.04 to 0.44; overall survival: HR=0.29, 95% CI=0.11 to 0.51) and imatinib treatment (relapse-free survival: HR=0.14, 95% CI=0.02 to 0.81; overall survival: HR=0.29, 95% CI=0.17 to 0.48). Caveolin-1 represents a novel prognostic marker in gastrointestinal stromal tumours. Further studies are warranted to validate these results and to explore the mechanisms linking Caveolin-1 expression with the PDGFRA oncogenic pathway. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Report this publication

Statistics

Seen <100 times